While we and others have previously performed this screen for the discovery of cancer genes involving cell proliferation or tumor growth [4,5], it has also been applied to identify genes involved in drug susceptibility/resistance in several cancer types, including the BRAF inhibitor for melanoma and the FLT3 inhibitor for acute myeloid leukemia [6,7]. The gene discussed is FLT3; the disease is cancer.